Neurocrine Biosciences has initiated a Phase 1 clinical trial to test the safety and tolerability of NBIP-‘1968, a novel triple agonist drug targeting GLP-1, GIP, and glucagon receptors for obesity treatment. This investigational drug aims to address obesity by engaging three metabolic mechanisms to regulate appetite, energy balance, and glycemic control. The study will involve single ascending doses in adults with varying body mass indexes. NBIP-‘1968 is part of Neurocrine’s broader obesity portfolio, which includes other investigational drugs, reflecting the company’s commitment to developing new therapies for this complex chronic disease with significant health impacts worldwide.
More News (NBIX)
Rare endocrine and obesity drug acquisitions hit $12.9B; new MC4R therapies show promise but face tolerability challenges
In the past four months, rare endocrine and obesity drug acquisitions totaled about $12.9 billion, highlighting strong investor interest. Rhythm Pharmaceuticals’ IMCIVREE, an FDA-approved MC4R agonist for rare obesity disorders, generated $71.3 milli
Market News
Bullish
2 days ago
